Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02875067 · ClinicalTrials.gov registry record · Phase 1
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
A Phase 1 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02875067 is a Phase 1 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT02875067, a Phase 1 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This trial is to assess the safety \& efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2017-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02875067
The ClinicalTrials.gov registry entry for NCT02875067 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02875067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02875067 about?
NCT02875067 is a clinical study titled "Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma". This trial is to assess the safety \& efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.
What is the current status of trial NCT02875067?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-08-29. Estimated completion is 2017-10-02.
What interventions are being tested in trial NCT02875067?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02875067?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.